Nordic Science Capital

Investing in groundbreaking technologies means actively shaping the future. Passion is what drives us. Look deeper is our approach. About Onsight Ventures Think globally, act locally. We bring together bright minds to create technologies that have a global impact. Based in Innsbruck, Onsight Ventures is setting new momentum for high-tech start-ups in Austria and Europe. Supported by founding partners Hermann Hauser Investment, Round2 Capital, I.E.C.T., and Standortagentur Tirol, Onsight Ventures builds on a Europe-wide network of industry leading start-ups, universities and experts, to work closely with and support outstanding management teams in the implementation of their technology-based business ideas. Our vision – to work with tomorrow's most outstanding entrepreneurs today. Our goal – to support the development of young companies in reaching their goals and thus partake in actively shaping the future. Our core valuesAmbition: BioNTech, a company largely unknown before the COVID crisis, is making history. This has been achieved following the founding of a successful spin-off, led by three physicians - including Tyrolean Christoph Huber, a member of the Onsight advisory board. Excellence: We don't have to look to Silicon Valley or China for inspiration or knowledge; here in Europe we have excellent university and non-institute-based research.There is no lack of innovation. Convinced by their potential, our sweet spot is academic start-ups and university spin-offs. Impact: The 21st century is presenting us and our planet with major challenges. We are convinced that young entrepreneurs can achieve a positive impact with their technologies and business models by pursuing their goals with passion. Our responsibility as an investor is to help sustainable technologies grow both capital and know-how. Integrity: Entrepreneurship is a team sport. The road to building an internationally successful company is a rocky one. That's why trust, honesty and integrity play a crucial role in the long-term cooperation between founder teams and investors.

AdBio partners (formerly Advent France Biotechnology) is a venture capital firm investing in early stage life sciences companies in Europe. AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth. As an early-stage investor, we act as a catalyst to create companies based on innovations coming from academic research. We have established relationships with leading research institutions and technology transfer offices in Europe and benefit from the support of strong network of scientific, clinical, industry and financial partners. The operational team is managed by Alain Huriez, MD, Chairman and Managing Partner, and Geoffroy de Ribains, Managing Partner. The team includes seasoned investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise.

We invest in visionary science start-ups. As part of the xista ecosystem, set up by the Institute of Science and Technology Austria, xista science ventures speak the language of scientist and investor. This makes us a unique partner to fuel founders’ deep tech ideas and help build exciting, scalable companies. Our understanding of academic spin-offs and the deep tech founders landscape, allows xista science ventures to recognise, analyse and propel companies to the next stage. We encourage the cross-fertilisation of startups to inspire new discoveries. Let us learn and profit from each other.

Since its genesis at the University of Oxford in 2015, Panacea Innovation has partnered with some of the world’s best sci-entrepreneurs, research bodies, universities and corporates to build more than 280 companies that offer cutting-edge solutions - curating a portfolio of more than GBP£300m in value. Panacea Innovation’s venturing activities are delivered through two complementary arms: Panacea Stars - a technology translation, commercialisation and R&D arm - and Panacea Ventures, the investment management one.

Our Ventures team supports the launch of startups based on University of Michigan technologies and research discoveries. We provide a full suite of resources, services and funding to help you launch sustainable, impactful world changing startups. The Ventures team will engage with you from day one to establish clear and executable commercialization, business formation and funding strategies. As your startup project begins to take form we can provide grant funding and investment capital, as well as business know-how, talent resources and connections to a nationwide network of investors. Whether it is helping you find the perfect team member, investment partner or connecting you with service providers, we have you covered.

We have a unique setup that combines venture creation and tech investments within a single organization. This advantage enables us to identify new research and deep tech opportunities with both commercial and impact potential, all within Chalmers’ entrepreneurial ecosystem. We are experts in starting up companies based on deep tech and research in the most effective manner possible. This process allows us to cultivate our own high-quality deal flow in which we invest and become active owners. Throughout the entire journey, we function as investors and venture builders until exit. Profits are reinvested through our evergreen model and allocated to Chalmers to support new, groundbreaking research. Our investment processWe identify market potential in research-based tech We match the team We invest in and startup the company We attract competent capital with external VCs We have active ownership until exit Our deal flow criteriaDeep tech / research based tech University spinouts Global commercial and impact potential Our process: from lab to market We use our long experience to create conditions required for a growth company to start up correctly and with the right structural capital. We are then involved in the startup through competence and capital until exit. Simply put: we take groundbreaking research from lab to market. IDENTIFY: We attract, seek out and evaluate research and technology ideas. The technologies with the greatest potential are matched with entrepreneurs. SHAPE AND START: Create the basic conditions to shape companies correctly and build structural capital. We are involved in starting up the companies and provides additional benefits during that first critical period. VALIDATE & VERIFY: Validating business model, working for paying customers and unlocking the business model. Find the right proof points to validate and verify the company’s unique idea to both the market and investors. SCALE: Becoming sustainable growth companies reaching out to an international market. Chalmers Ventures works with its skills as active owners, provides professional governance and syndicates the right growth capital. EXIT: Chalmers Ventures pursues a positive exit strategy at what it feels is the right time. We can focus our resources on those companies with the greatest potential and positive impact on the portfolio.